Evkeeza Side Effects

Generic name: evinacumab

Medically reviewed by Drugs.com. Last updated on Mar 20, 2023.

Note: This document contains side effect information about evinacumab. Some dosage forms listed on this page may not apply to the brand name Evkeeza.

Applies to evinacumab: intravenous solution.

Serious side effects of Evkeeza

Along with its needed effects, evinacumab (the active ingredient contained in Evkeeza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking evinacumab:

Less common

Chest tightness
cough
difficulty swallowing
dizziness
fast heartbeat
hives, itching, skin rash
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
trouble breathing
unusual tiredness or weakness

Other side effects of Evkeeza

Some side effects of evinacumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Chills
diarrhea
fever
general feeling of discomfort or illness
headache
itching at the injection site
joint pain
loss of appetite
muscle aches, pains, or weakness
nausea
shivering
sore throat
stuffy or runny nose
sweating
trouble sleeping
vomiting

Less common

Body aches or pain
constipation
ear congestion
lack or loss of strength
loss of voice
pain in the arms or legs
sneezing
stomach pain

For Healthcare Professionals

Applies to evinacumab: intravenous solution.

General

The more frequently reported adverse reactions have included nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea.^[Ref]

Hypersensitivity

Anaphylaxis was reported in 1 patient receiving this drug during clinical trials and led to discontinuation of treatment.

Uncommon (0.1% to 1%): Anaphylaxis

Respiratory

Compared to placebo, upper respiratory tract infection and nasal congestion were reported at a higher incidence; incidence was less than 3% of patients.

Very common (10% or more): Nasopharyngitis (16%)

Common (1% to 10%): Rhinorrhea

Frequency not reported: Upper respiratory tract infection, nasal congestion

Immunologic

Frequency not reported: Influenza-like illness

Compared to placebo, influenza-like illness was reported at a higher incidence; incidence was less than 3% of patients.

Cardiovascular

During clinical trials, transient decreases in diastolic blood pressure and increases in heart rate occurred but did not require intervention and resolved post infusion.

Frequency not reported: Diastolic blood pressure decreased, increased heart rate

Nervous system

Common (1% to 10%): Dizziness

Gastrointestinal

Compared to placebo, constipation and abdominal pain were reported at a higher incidence; incidence was less than 3% of patients.

Common (1% to 10%): Nausea

Frequency not reported: Constipation, abdominal pain

Musculoskeletal

Common (1% to 10%): Extremity pain

Other

Common (1% to 10%): Asthenia

Local

Infusion site reactions including infusion site pruritus, pyrexia, muscular weakness, nausea, and nasal congestion were reported in 7% of patients (n=6) receiving this drug compared to 4% (n=2) of placebo patients.

Common (1% to 10%): Infusion site reactions